Galectin Therapeutics (GALT) Projected to Post Earnings on Monday

Galectin Therapeutics (NASDAQ:GALT) will likely be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Galectin Therapeutics to post earnings of ($0.10) per share and revenue of $36.32 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Galectin Therapeutics Stock Down 4.3%

Shares of Galectin Therapeutics stock opened at $2.68 on Friday. Galectin Therapeutics has a 12-month low of $1.12 and a 12-month high of $7.13. The stock has a 50 day moving average price of $2.99 and a two-hundred day moving average price of $4.26. The stock has a market capitalization of $172.78 million, a P/E ratio of -4.54 and a beta of 0.98.

Insider Buying and Selling at Galectin Therapeutics

In other news, CEO Joel Lewis sold 37,698 shares of Galectin Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $3.58, for a total value of $134,958.84. Following the completion of the transaction, the chief executive officer owned 832,592 shares in the company, valued at approximately $2,980,679.36. The trade was a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jack W. Callicutt sold 25,732 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $3.90, for a total value of $100,354.80. Following the sale, the chief financial officer owned 27,968 shares in the company, valued at approximately $109,075.20. This trade represents a 47.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 204,000 shares of company stock worth $787,433 over the last ninety days. Corporate insiders own 52.60% of the company’s stock.

Institutional Investors Weigh In On Galectin Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of Galectin Therapeutics during the second quarter valued at $1,580,000. Goldman Sachs Group Inc. increased its position in Galectin Therapeutics by 1,295.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 307,229 shares of the company’s stock worth $1,278,000 after purchasing an additional 285,215 shares during the period. 683 Capital Management LLC bought a new stake in Galectin Therapeutics during the 4th quarter worth about $676,000. Wellington Management Group LLP bought a new stake in Galectin Therapeutics during the 4th quarter worth about $592,000. Finally, Millennium Management LLC lifted its position in Galectin Therapeutics by 113.3% during the 4th quarter. Millennium Management LLC now owns 235,508 shares of the company’s stock valued at $980,000 after purchasing an additional 125,086 shares during the period. Institutional investors own 11.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GALT. HC Wainwright boosted their target price on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.